Labetalol
Indications
Labetalol occupies a distinctive niche in cardiovascular pharmacotherapy: it is the only widely used antihypertensive that combines α1-adrenergic blockade (vasodilation) with non-selective β-blockade (negative chronotropy, inotropy, and dromotropy) within a single molecule. The result is reliable blood-pressure reduction without reflex tachycardia — particularly useful in acute haemodynamic management, hypertensive emergencies, and pregnancy.
| Indication | Population / Formulation | Therapy Type | Status |
|---|---|---|---|
| Hypertension — to lower blood pressure and reduce risk of fatal and non-fatal cardiovascular events | Adults; oral tablets (100, 200, 300 mg) | Monotherapy or combination, especially with thiazide and loop diuretics | FDA Approved (oral) |
| Severe hypertension — for control of blood pressure in severe hypertension in hospitalised patients per the Trandate Injection labelling | Adults; injection (5 mg/mL) | IV slow push or continuous infusion in monitored setting | FDA Approved (Trandate Injection) |
| Hypertension in pregnancy (chronic hypertension, gestational hypertension, pre-eclampsia) | Pregnant adults; oral and IV | First-line per ACOG; oral for chronic management, IV for acute severe-range BP | Off-Label (guideline first-line) |
| Hypertensive emergency in non-pregnant adults — rapid BP control in acute end-organ-threatening hypertension | Adults; IV in monitored setting | Among preferred first-line agents per ESC and major reviews | Off-Label (guideline-supported) |
| Pheochromocytoma — adjunctive blood-pressure and symptom control after adequate alpha-blockade | Adults | Adjunct to phenoxybenzamine or doxazosin; per the FDA PI, higher than usual doses may be required and paradoxical hypertensive responses have been reported | Off-Label (mentioned in Trandate Injection labelling) |
| Acute aortic dissection — initial blood-pressure and shear-stress control | Adults; IV in monitored setting | Preferred agent in many institutional protocols (alongside esmolol) | Off-Label (guideline-supported) |
| Hypertension in acute ischaemic stroke — when blood-pressure lowering is indicated (e.g., for thrombolysis eligibility) | Adults; IV | One of the recommended IV agents per AHA/ASA guidelines | Off-Label (guideline-supported) |
| Perioperative / intraoperative hypertension | Adults; IV | Acute control during anaesthesia and post-operative period | Off-Label (well-established practice) |
| Autonomic dysreflexia in spinal cord injury | Adults; IV or oral | Symptomatic adrenergic control | Off-Label |
| Cocaine- or methamphetamine-induced hypertension | Adults; IV | Selected as it provides both alpha- and beta-blockade in a single agent | Off-Label (institutional protocols vary) |
The 2024 FDA-approved indication for oral labetalol is hypertension only. The Trandate Injection labelling supports use for control of blood pressure in severe hypertension. Other applications — including pregnancy hypertension, hypertensive emergency in non-pregnant adults, aortic dissection, and acute stroke — are off-label but extensively supported by major guideline organisations including ACOG, AHA/ASA, and the European Society of Cardiology.
Pregnancy hypertension and pre-eclampsia — Per ACOG Practice Bulletin 203, labetalol is one of the preferred oral agents for chronic hypertension in pregnancy (alongside extended-release nifedipine; methyldopa and hydrochlorothiazide are secondary). Per ACOG Committee Opinion 767, IV labetalol is one of three first-line agents for acute-onset severe hypertension in pregnancy (alongside IV hydralazine and immediate-release oral nifedipine). The CHIPS trial (Magee 2015) and CHAP trial (Tita 2022) provided contemporary evidence on BP targets in pregnancy. Evidence quality: high.
Hypertensive emergency — IV labetalol is among the preferred agents for rapid BP reduction in most hypertensive emergencies and is particularly useful in acute aortic dissection because of its concurrent negative chronotropic and inotropic effects on aortic shear stress. Evidence quality: high (long-standing clinical practice).
Acute ischaemic stroke — Per AHA/ASA stroke guidelines, IV labetalol is one of the recommended agents for blood-pressure lowering when needed before thrombolysis (target <185/110 mmHg) or for severely elevated BP after stroke. Evidence quality: high (guideline-supported).
Dosing
| Clinical Scenario | Starting Dose | Titration / Maintenance | Maximum Dose | Notes |
|---|---|---|---|---|
| Hypertension — adult, oral (FDA-approved) | 100 mg PO twice daily alone or added to a diuretic regimen | Adjust in increments of 100 mg twice daily at 2–3-day intervals; usual maintenance 200–400 mg twice daily per the FDA PI | Per the FDA PI: severe hypertension may require 1,200–2,400 mg/day (titrate in increments not to exceed 200 mg twice daily) | Steady-state BP response within 24–72 hours of dosing Twice-daily dosing reflects pharmacokinetics |
| Hypertension — elderly, oral | 100 mg PO twice daily | Many elderly patients require 100–200 mg twice daily per the FDA PI | Per response and tolerability | Elderly are more likely to experience orthostatic hypotension, dizziness, and lightheadedness |
| Severe hypertension — adult, IV bolus per Trandate Injection labelling | 20 mg IV slow injection over 2 minutes (corresponds to 0.25 mg/kg for an 80-kg patient) | Additional injections of 40 or 80 mg at 10-minute intervals until target BP achieved | 300 mg cumulative per the Trandate Injection labelling | Patient must remain supine during and for up to 3 hours after IV administration. Continuous BP monitoring; supine BP measured immediately before injection and at 5 and 10 minutes after Maximal effect of each dose typically within 5 minutes; BP rises gradually toward baseline within average 16–18 hours after IV discontinuation |
| Severe hypertension — adult, IV continuous infusion | Prepare 1 mg/mL solution by diluting 40 mL Trandate Injection in 160 mL IV fluid; infuse at 2 mL/min to deliver 2 mg/min | Adjust rate per BP response; effective IV dose usually 50–200 mg per the Trandate Injection labelling | 300 mg cumulative per the Trandate Injection labelling; up to 3 g/day over 2–3 days has been anecdotally reported (with hypotension or bradycardia in some patients) | Steady-state blood levels not reached during typical infusion duration; controlled administration via burette or infusion pump preferred |
| Transition from IV to oral therapy | Per the Trandate Injection PI: begin oral dosing when supine diastolic BP has begun to rise. Initial oral dose 200 mg PO | Followed in 6–12 hours by an additional 200 or 400 mg PO, depending on BP response | Per inpatient titration table: 200 BID → 400 BID → 800 BID → 1,200 BID (max 2,400 mg/day, ± three divided doses) | Inpatient titration may proceed at 1-day intervals to achieve desired BP reduction |
| Acute severe hypertension in pregnancy — IV (off-label, ACOG-supported) | 20 mg IV slow push over 2 minutes if BP remains ≥160/110 mmHg after 15 minutes | Repeat at 40 mg, then 80 mg, then 80 mg IV at 10–15-minute intervals until target BP achieved | 220 mg cumulative per ACOG protocols; consider alternative agent if not controlled at this dose | Continuous fetal monitoring; transition to oral once stable. Avoid in patients with bradycardia or asthma IV hydralazine and oral immediate-release nifedipine are the alternatives per ACOG Committee Opinion 767 |
| Chronic hypertension in pregnancy — adult, oral (off-label, ACOG first-line) | 100 mg PO twice daily | Increase as needed; usual maintenance up to 2,400 mg/day divided | 2,400 mg/day per the FDA oral PI | Alongside extended-release nifedipine, one of the preferred first-line oral agents for chronic HTN in pregnancy per ACOG Practice Bulletin 203. Monitor maternal BP, HR, LFTs and fetal growth |
| Acute aortic dissection — adult, IV (off-label, guideline-supported) | 20 mg IV slow push followed by infusion typically 2 mg/min | Titrate to SBP 100–120 mmHg and HR <60 bpm | Per haemodynamic targets | Combined alpha- and beta-blockade ideal for shear-stress reduction. Esmolol is an alternative when shorter half-life is preferred |
| Hypertension in acute ischaemic stroke — IV (off-label, AHA/ASA-supported) | 10–20 mg IV over 1–2 minutes | May repeat once after 10–20 minutes; continuous infusion can be used per institutional protocol | Per BP target | Goal BP <185/110 mmHg before thrombolysis; <180/105 mmHg during/after thrombolysis |
| Discontinuation | Reduce gradually; per the FDA PI, do not abruptly discontinue | Abrupt withdrawal may cause exacerbation of angina or, in some cases, MI in patients with coronary artery disease | ||
Population-Specific Considerations
| Population | Adjustment | Rationale |
|---|---|---|
| Renal impairment | No formal adjustment | Per the FDA PI, the elimination half-life of labetalol is not altered in renal impairment; not significantly removed by haemodialysis or peritoneal dialysis (<1%) |
| Hepatic impairment | Use with caution; consider lower starting dose | Per the FDA PI, half-life is not altered but bioavailability is increased due to decreased first-pass metabolism. Hepatocellular injury (rare but potentially fatal) warrants monitoring for symptoms |
| Elderly | Initiate at standard 100 mg BID; many require lower maintenance dosing | Per the FDA PI, elimination is reduced in elderly patients; orthostatic hypotension and dizziness more common |
| Paediatric | Safety and effectiveness not established | Per the FDA PI; off-label use exists in paediatric hypertensive emergency at 0.2–1 mg/kg IV bolus or continuous infusion per institutional protocol |
| Pregnancy | Used at standard adult dosing; preferred agent in many guideline-supported scenarios | Per the FDA PI, extensive published experience has not identified a drug-associated risk for major birth defects, miscarriage, or adverse maternal/fetal outcomes. Crosses placenta — neonates require monitoring at delivery |
| Lactation | Generally compatible | Per the Trandate Tablets PI, approximately 0.004% of the maternal dose is excreted in human milk |
The combination of α1-blockade (vasodilation, BP reduction) and non-selective β-blockade (negative chronotropy, attenuation of reflex tachycardia) gives labetalol four practical advantages: (1) predictable BP reduction without reflex tachycardia, (2) rapid onset (maximal effect within 5 minutes IV) suitable for hypertensive emergencies, (3) relatively short duration of action allowing easy titration, and (4) lack of significant CYP-mediated drug interactions (predominantly glucuronidated). The α:β ratio of approximately 1:7 with IV administration means labetalol behaves predominantly as a beta-blocker IV, with the alpha component contributing supplementary vasodilation — this is why it does not produce the dramatic BP drops sometimes seen with pure alpha-blockers.
Pharmacology
Mechanism of Action
Labetalol hydrochloride combines selective competitive α1-adrenergic blockade with non-selective competitive β-adrenergic blockade in a single molecule. Per the FDA PI, the α:β blockade ratio is approximately 1:3 after oral administration and 1:7 after intravenous administration. The α1-blockade attenuates the pressor response to phenylephrine and the cold-pressor test in humans, contributing peripheral vasodilation. β1-blockade decreases resting heart rate modestly, attenuates exercise-induced tachycardia, and blunts the reflex tachycardia produced by amyl nitrite-induced hypotension. β2-blockade is demonstrated by inhibition of isoproterenol-induced fall in diastolic blood pressure.
The net haemodynamic result is dose-related blood-pressure reduction without reflex tachycardia and without significant reduction in cardiac output, achieved through a balanced reduction of total peripheral resistance (from α1-blockade) and prevention of compensatory sympathetic responses (from β-blockade). Plasma renin activity is reduced. Because of α1-mediated postural vasodilation, blood pressure falls more in the standing than the supine position — the basis for the FDA-required supine positioning during and for 3 hours after IV administration.
Per the FDA PI, labetalol exists as a molecular complex of two diastereoisomeric pairs (four stereoisomers total). The R,R’-stereoisomer (dilevalol) accounts for 25% of racemic labetalol. Of historical relevance, dilevalol was developed as a separate single-isomer product but was withdrawn after reports of severe hepatic injury — a signal that informs labetalol’s hepatic safety surveillance, since dilevalol is one of the four isomers contained within labetalol.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Rapidly absorbed orally; peak plasma levels 1–2 hours after oral administration. Absolute bioavailability ~25% (extensive first-pass hepatic metabolism). Peak effect of single oral dose at 2–4 hours; duration ≥8 hours after 100 mg, >12 hours after 300 mg per the FDA PI. Bioavailability is increased by food | Twice-daily oral dosing; meals enhance absorption modestly. IV onset rapid (maximal effect within 5 minutes per the Trandate Injection PI) |
| Distribution | Approximately 50% protein-bound (lower than most beta-blockers). Crosses the placenta. Per the Trandate Injection PI, only negligible amounts of the drug crossed the blood-brain barrier in animal studies. Excreted in human milk at low levels (~0.004% of maternal dose per the Trandate Tablets PI) | Lower protein binding than propranolol or carvedilol; modest CNS penetration (less lipophilic than propranolol — fewer CNS adverse effects) |
| Metabolism | Mainly hepatic, predominantly via glucuronide conjugation (Phase II metabolism). Per the FDA PI, labetalol is not a major substrate of cytochrome P450 enzymes | Few clinically significant CYP-mediated drug interactions — a significant advantage over propranolol and metoprolol. The principal pharmacokinetic interaction noted in the PI is with cimetidine, which increases bioavailability |
| Elimination | Plasma half-life ~6–8 hours after oral administration; ~5.5 hours after IV infusion per the Trandate Injection PI. Steady state by ~third day of dosing. Approximately 55–60% excreted in urine as conjugates or unchanged labetalol within first 24 hours; biliary excretion to faeces accounts for the remainder. Not significantly removed by haemodialysis or peritoneal dialysis (<1%) | No renal-dose adjustment needed per the FDA PI. Dialysis does not enhance clearance in overdose |
Labetalol’s pharmacological profile sits between the pure beta-blockers (atenolol, metoprolol, propranolol) and the alpha/beta-blocker carvedilol. Compared with carvedilol, labetalol’s alpha component is more pronounced relative to its beta component, especially intravenously, and labetalol has IV availability — making it the drug of choice in acute settings where carvedilol’s chronic-only oral form is unsuitable. Compared with pure beta-blockers, labetalol is less likely to cause cold extremities (because alpha-blockade promotes peripheral vasodilation), less likely to provoke reflex tachycardia after vasodilator co-administration, and is preferred over propranolol in pregnancy. However, labetalol shares the bronchospasm risk of all non-selective beta-blockers and the orthostatic hypotension risk of alpha-blockers, particularly with the first dose or after IV administration.
Side Effects
Labetalol’s adverse effects reflect both alpha-1 antagonism (orthostatic hypotension, nasal stuffiness, intraoperative floppy iris syndrome) and non-selective beta-blockade (bradycardia, bronchospasm, hypoglycaemia masking). Per the FDA PI, in controlled clinical trials of 3 to 4 months’ duration, discontinuation of labetalol due to one or more adverse effects was required in 7% of all patients. Most adverse effects are mild and transient, occurring early in the course of treatment.
| Adverse Effect | Labetalol (n = 227) | Placebo (n = 98) | Clinical Note |
|---|---|---|---|
| Dizziness | 11% | 3% | Most common adverse effect; frequently orthostatic — counsel patients to rise slowly |
| Nausea | 6% | 1% | Usually mild and self-limited |
| Fatigue | 5% | 0% | Often improves over the first 2–4 weeks |
| Nasal stuffiness | 3% | 0% | Reflects α1-blockade in nasal mucosa — distinctive of α-blocker–containing antihypertensives |
| Dyspepsia | 3% | 1% | Take with food if bothersome |
| Headache | 2% | 1% | Often improves with continued therapy |
| Dyspnoea | 2% | 0% | May reflect early beta-blocker effect or unmasking of subclinical bronchospasm — assess history of reactive airways disease |
| Vertigo | 2% | 1% | Often related to orthostatic effect; transient |
| Adverse Effect | Daily Dose 200 mg | Daily Dose 800 mg | Daily Dose 2,400 mg |
|---|---|---|---|
| Dizziness | 2% | 5% | 16% |
| Fatigue | 2% | 5% | 10% |
| Nausea | <1% | 4% | 19% |
| Vomiting | 0% | <1% | 3% |
| Dyspepsia | 1% | 1% | 4% |
| Paresthesia | 2% | 1% | 5% |
| Nasal stuffiness | 1% | 2% | 6% |
| Ejaculation failure | 0% | 3% | 5% |
| Impotence | 1% | 2% | 3% |
| Oedema | 1% | 1% | 2% |
| Adverse Effect | Reported Frequency | Clinical Note |
|---|---|---|
| Symptomatic postural hypotension (if tilted within 3 hours) | 58% | Per the Trandate Injection PI; the basis for the supine-positioning requirement |
| Nausea | 13 per 100 | Often mild |
| Dizziness | 9 per 100 | Particularly during BP nadir |
| Transient elevation in BUN / creatinine | 8 per 100 | Per the Trandate Injection PI, generally associated with drops in blood pressure in patients with prior renal insufficiency |
| Tingling of scalp / skin | 7 per 100 | Distinctive to labetalol; transient and usually resolves with continued therapy |
| Sweating | 4 per 100 | Usually transient |
| Vomiting | 4 per 100 | Mild and self-limiting |
| Somnolence / yawning | 3 per 100 | Reflects post-administration BP reduction |
| Moderate hypotension (supine) | 1 per 100 | Manage with supine positioning, leg elevation, IV fluids |
| Ventricular arrhythmia, hypoaesthesia, vertigo, flushing, wheezing, pruritus | 1 per 100 each | Per the Trandate Injection PI; uncommon but reported |
| Adverse Effect | Reported Frequency | Clinical Note |
|---|---|---|
| Reversible elevation in serum transaminases (oral) | ~4% of patients tested per the Trandate Injection PI (referencing oral data) | Mostly mild and reversible; severe hepatocellular injury is rare but a recognised serious adverse reaction |
| Tremor (with concomitant TCA) | 2.3% with TCA vs 0.7% with labetalol alone per the FDA PI | Distinctive interaction; dose adjustment of either agent may be needed |
| Postural / orthostatic hypotension (oral) | ~2% in oral trials; more common with first dose and large dose increases | Most likely 2–4 hours after a dose, especially with large initial doses or large changes in dose per the FDA PI |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Severe hepatocellular injury (hepatic necrosis, hepatitis, cholestatic jaundice) | Rare per the FDA PI; usually reversible but hepatic necrosis and death have been reported. Confirmed by rechallenge in at least one case per the Trandate Injection PI | After short- or long-term treatment; may be slowly progressive despite minimal symptoms | Discontinue labetalol if signs/symptoms of liver injury develop. Investigate cause; per the FDA PI, do not restart unless another explanation found |
| Severe orthostatic hypotension / syncope | More likely with first dose and after large dose increases per the FDA PI | 2–4 hours after dose | Patient supine; legs elevated; IV fluids if severe. After IV labetalol, patient must remain supine during and for up to 3 hours after administration |
| Bradycardia, sinus pause, heart block, cardiac arrest | Rare; risk increased with concomitant non-DHP CCB or digitalis per the FDA PI | Hours to days | Hold drug; atropine; transcutaneous or transvenous pacing for high-degree AV block; IV glucagon for refractory beta-blocker toxicity |
| Bronchospasm | Bronchial asthma and obstructive airway disease are absolute contraindications per the FDA PI | Within hours | Avoid in reactive airways disease; inhaled β2-agonist (high doses may be required); systemic corticosteroids if severe |
| Heart failure precipitation / decompensation | Decompensated heart failure is an absolute contraindication; overt CHF is also contraindicated per the FDA PI | Days to weeks | Discontinue if signs/symptoms of HF develop; treat appropriately. Labetalol is NOT FDA-approved for chronic heart failure (carvedilol is the alpha/beta-blocker for HF) |
| Severe / prolonged hypoglycaemia | Risk increased especially in patients with diabetes mellitus, children, and fasting patients per the FDA PI | During hypoglycaemic episodes | Beta-blockers may mask early warning signs (tachycardia); counsel diabetics. Increase glucose monitoring frequency |
| Paradoxical hypertensive response in pheochromocytoma | Reported in a few patients per the FDA PI | During treatment | Higher than usual doses may be needed for pheochromocytoma; monitor BP closely; alpha-blockade should be established first |
| Anaphylactic / anaphylactoid reactions with relative resistance to adrenaline | Per the FDA PI; reported in patients on beta-blockers | Variable | Avoid labetalol in patients at high risk of anaphylaxis per the FDA PI. Higher-dose adrenaline, IV glucagon, IV fluids, antihistamines, corticosteroids |
| Intraoperative floppy iris syndrome (IFIS) during cataract surgery | Per the FDA PI; observed in patients treated with α1-blockers (labetalol is alpha/beta) | Intraoperative | Inform the patient’s ophthalmologist preoperatively. Surgical modifications (iris hooks, dilator rings, viscoelastics) may be needed. Per the Trandate Injection PI, no benefit demonstrated for stopping alpha-1 blocker therapy prior to cataract surgery |
| Severe hypotension during halothane anaesthesia | Synergism between IV labetalol and halothane per the FDA PI | Intraoperative | Avoid high-concentration halothane (≥3%) with IV labetalol; communicate with anaesthesia team about beta-blocker therapy |
| Acute exacerbation of angina or MI on abrupt withdrawal | Class effect per the FDA PI | Days after stopping | Do not abruptly discontinue; taper gradually. If angina worsens, promptly reinstitute and manage as unstable angina |
| Cutaneous reactions including rash, urticaria, pruritus, angioedema | Rare per the Trandate Injection PI; hypersensitivity reactions reported | Variable | Discontinue; treat as for hypersensitivity |
Per the FDA PI, overdosage with labetalol causes excessive hypotension that is posture-sensitive and sometimes excessive bradycardia. Critical management points: (1) Place patient supine and elevate legs to improve cerebral perfusion. (2) Excessive bradycardia: atropine or epinephrine; cardiac failure: digitalis glycoside and diuretic, with dopamine or dobutamine if needed. (3) Hypotension: vasopressors (norepinephrine may be the drug of choice per the Trandate Injection PI). (4) Bronchospasm: epinephrine and/or aerosolised β2-agonist. (5) Per the Trandate Injection PI, in severe beta-blocker overdose with hypotension and/or bradycardia, glucagon has been shown to be effective when administered as 5–10 mg rapidly over 30 seconds, followed by continuous infusion of 5 mg/h that can be reduced as the patient improves. (6) Seizures: diazepam. (7) Per the FDA PI, neither haemodialysis nor peritoneal dialysis removes a significant amount of labetalol (<1%).
Drug Interactions
Labetalol’s interaction profile is notably narrower than that of CYP-metabolised beta-blockers (propranolol, metoprolol, carvedilol) because labetalol is primarily eliminated by glucuronide conjugation, not by CYP enzymes. The clinically important interactions are pharmacodynamic (additive haemodynamic effects with other negative chronotropes, bronchodilator antagonism, halothane synergism, anaesthetic interactions) rather than pharmacokinetic. The 2024 FDA oral PI also flags a notable diagnostic-laboratory interaction relevant to pheochromocytoma evaluation.
(1) Non-DHP CCB combination is contraindicated per the 2024 FDA oral PI — a uniquely strong restriction for labetalol (most beta-blockers carry only a “use caution” warning for this combination). Use amlodipine instead. (2) Halothane anaesthesia synergism — communicate labetalol therapy to the anaesthesia team; high-concentration halothane (≥3%) is contraindicated. (3) Falsely elevated urinary catecholamines — important to remember when evaluating possible pheochromocytoma in a patient already taking labetalol; insist on HPLC-based assay or hold labetalol and use plasma-free metanephrines.
Monitoring
-
Blood Pressure (Supine and Standing)
Baseline, at each titration step, then routinely
Routine Per the FDA PI, monitor for symptomatic postural hypotension and syncope after initial dosing or dose increments. Symptomatic postural hypotension is most likely 2–4 hours after a dose. For IV labetalol, supine BP measured immediately before injection and at 5 and 10 minutes after; supine positioning during and for up to 3 hours after IV administration. -
Heart Rate
Baseline, at each titration step, then routinely
Routine Per the FDA PI, monitor heart rate and rhythm in patients receiving labetalol. Bradycardia, sinus pause, heart block, severe bradycardia, and cardiac arrest have occurred with beta-blockers. -
Liver Function Tests (LFTs)
If symptoms develop; baseline reasonable; periodic determination considered appropriate per the Trandate Injection PI
Trigger-based Per the FDA PI, severe hepatocellular injury occurs rarely with labetalol therapy. Hepatic injury is usually reversible, but hepatic necrosis and death have been reported. Investigate the probable cause of any signs/symptoms of liver injury (pruritus, dark urine, persistent anorexia, jaundice, right-upper-quadrant tenderness, unexplained “flu-like” symptoms). Do not restart labetalol without another explanation. -
ECG
Baseline if conduction concerns; for symptomatic bradycardia
Trigger-based Particularly important in patients with pre-existing first-degree AV block (a relative contraindication unless paced) or sinus node dysfunction. -
Respiratory Symptoms
At each visit; particularly if any history of reactive airways disease
Routine Bronchial asthma is an absolute contraindication. New wheezing or dyspnoea warrants urgent reassessment; per the FDA PI, avoid labetalol in patients with reactive airways disease. -
Glycaemic Status (in diabetics)
Routine in diabetics
Routine Per the FDA PI, beta-blockers may prevent early warning signs of hypoglycaemia (tachycardia) and increase risk for severe or prolonged hypoglycaemia, especially in diabetics, children, and fasting patients. -
Maternal/Fetal Surveillance (in Pregnancy)
Per obstetric protocol
Routine Routine BP, HR, and LFT monitoring; serial fetal growth assessment given association of maternal hypertension with intrauterine growth restriction. At delivery, neonatal monitoring for hypotension, bradycardia, hypoglycaemia, and respiratory depression per the FDA PI. -
Pre-Cataract Surgery Communication
Before any planned cataract surgery
Trigger-based Per the FDA PI, intraoperative floppy iris syndrome has been observed during cataract surgery in patients treated with α1-blockers. Inform the patient’s ophthalmologist preoperatively. Per the Trandate Injection PI, no benefit demonstrated for stopping alpha-1 blocker therapy prior to cataract surgery. -
Pre-Surgery Communication
Before any planned surgery
Trigger-based Per the FDA PI, do not routinely withdraw chronic beta-blocker therapy prior to surgery. The effect of labetalol’s alpha-adrenergic activity has not been fully evaluated in this setting. Communicate beta-blocker use and recent dose to anaesthetist; halothane synergism may warrant alternative anaesthetic agent. -
Adherence and Withdrawal Risk
At each follow-up
Routine Per the FDA PI, abrupt cessation of therapy with beta-blockers in patients with coronary artery disease can cause exacerbations of angina pectoris and, in some cases, MI. Counsel patients to refill in advance and never run out.
For routine outpatient labetalol monitoring, BP (both supine and standing) and HR are the primary parameters at every visit. For inpatient IV use, continuous BP and HR monitoring with supine positioning during and for 3 hours after administration is mandatory per the FDA PI. LFTs are not strictly required but should be checked at the first sign of symptoms suggesting liver injury — labetalol’s hepatotoxicity is rare but recognised and potentially serious. Per the Trandate Injection PI, periodic LFT determination is considered appropriate for chronic therapy.
Contraindications & Cautions
Absolute Contraindications (per the 2024 FDA Labetalol Tablets PI)
- Bronchial asthma or obstructive airway disease — non-selective β-blockade can provoke severe bronchospasm
- Decompensated heart failure — beta-blockade may further depress myocardial contractility and precipitate more severe failure
- Greater than first-degree heart block
- Cardiogenic shock
- Severe bradycardia
- Hypersensitivity reactions, including anaphylaxis, to labetalol
- Concomitant non-dihydropyridine calcium-channel antagonists (verapamil, diltiazem) — additive AV nodal slowing risk
Relative Contraindications (Specialist Input Recommended)
- Reactive airways disease (non-asthmatic) — avoid use; if essential, use the smallest effective dose to minimise inhibition of endogenous or exogenous beta-agonists
- Overt congestive heart failure — avoid use; if HF develops during therapy, discontinue
- Active untreated pheochromocytoma — alpha-blockade should be established first; per the FDA PI, paradoxical hypertensive responses have been reported in a few patients
- Severe hepatic impairment — bioavailability is increased; rare but potentially fatal hepatotoxicity
- History of severe acute hypersensitivity reactions — beta-blocker may blunt response to adrenaline used for treatment; avoid in patients at high risk per the FDA PI
- Impending iobenguane (MIBG) imaging — discontinue for at least 5 half-lives before scan
- Following coronary artery bypass surgery with low cardiac index and elevated systemic vascular resistance — per the Trandate Injection PI, IV labetalol use should be avoided in this specific subset
Use with Caution
- First-degree AV block, sinus node dysfunction — risk of progression with beta-blockade
- Diabetes mellitus, especially insulin-treated — masking of hypoglycaemic warning signs; per the FDA PI, increased risk of severe/prolonged hypoglycaemia, especially in fasting patients
- Major surgery — per the FDA PI, do not routinely withdraw chronic beta-blocker therapy prior to surgery; the effect of labetalol’s alpha-adrenergic activity has not been fully evaluated in this setting. Per the Trandate Injection PI, several deaths have occurred when Trandate Injection was used during surgery
- Coronary artery disease — do not abruptly discontinue (rebound angina, MI risk)
- Active hepatobiliary disease — increased exposure due to reduced first-pass; monitor for symptoms of hepatotoxicity
- Concurrent non-DHP CCB therapy — contraindicated per the FDA PI; if any beta-blocker is required with verapamil/diltiazem, choose a different agent
- Concurrent halothane anaesthesia — avoid concentrations ≥3% with IV labetalol
- Patients undergoing or scheduled for cataract surgery — IFIS risk; pre-operative ophthalmology communication
Labetalol does not carry an FDA boxed warning. The FDA prescribing information emphasises several distinctive cautions: (1) Concomitant use with non-DHP calcium-channel blockers is contraindicated — a stronger restriction than for most beta-blockers. (2) Bronchial asthma and obstructive airway disease are absolute contraindications because of non-selective β-blockade. (3) Severe hepatocellular injury, although rare, may be fatal — the PI specifies that labetalol should not be restarted in patients without another explanation for observed liver injury. (4) Halothane synergism mandates that high-concentration halothane (≥3%) not be used with IV labetalol, and per the Trandate Injection PI, several deaths have occurred when the injection was used during surgery. (5) Intraoperative floppy iris syndrome (a known α1-blocker effect) requires preoperative communication with ophthalmologists planning cataract surgery. (6) Strict supine positioning is required during and for 3 hours after IV administration to prevent symptomatic orthostatic hypotension (incidence 58% if patients are tilted within this window).
Patient Counselling
Purpose of Therapy
Explain that labetalol is a blood-pressure medicine that works in two ways at once: it relaxes the blood vessels (the “alpha” part) and slows the heart slightly (the “beta” part). This combination gives smooth blood-pressure control without the racing heartbeat that can happen with vessel-relaxing medicines alone. It is widely used for everyday high blood pressure, in pregnancy, and in hospital settings to bring dangerously high blood pressure down quickly.
How to Take
Take labetalol exactly as prescribed, usually twice a day. Take it with food — meals actually help the medicine absorb better. Take it consistently, the same way each time. Do not crush, chew, or split the tablets unless your prescriber tells you to. Do not stop suddenly. If you stop labetalol abruptly, your blood pressure can rebound, your heart rate can speed up, and in people with heart disease, this can trigger chest pain or even a heart attack. If you need to stop the medicine, your prescriber will guide you through a gradual taper.
Sources
- U.S. Food and Drug Administration. Labetalol Hydrochloride Tablets prescribing information. Alvogen, Inc. Revised April 2024. FDA label PDF Primary source for the 2024 oral labetalol indication, dosing, contraindications (including the unusual contraindication of concomitant non-DHP CCBs), pharmacokinetics, and adverse-event Table 1 with placebo-controlled incidence rates. Confirms Initial U.S. Approval date of 1984.
- U.S. Food and Drug Administration. Trandate (labetalol hydrochloride) Tablets prescribing information. FDA label PDF Brand-name reference label with detailed lactation data (~0.004% of maternal dose excreted in human milk) and elderly-population information.
- U.S. Food and Drug Administration. Trandate (labetalol hydrochloride) Injection prescribing information. FDA label PDF Source for IV bolus and continuous-infusion dosing, IV-specific α:β ratio of 1:7, supine positioning requirement, dose-stratified AE table across daily doses 200–2,400 mg, IV-specific AE rates per 100 patients (including 58% postural hypotension if tilted within 3 hours), the dilevalol hepatotoxicity historical context, and overdose management with glucagon 5–10 mg over 30 seconds followed by 5 mg/h infusion.
- Magee LA, von Dadelszen P, Rey E, et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015;372(5):407-417. DOI: 10.1056/NEJMoa1404595 CHIPS (Control of Hypertension In Pregnancy Study) trial — randomised non-inferiority trial comparing less-tight versus tight control of non-severe maternal hypertension; labetalol was the most commonly used antihypertensive. Tight control reduced severe hypertension without adverse perinatal outcomes.
- Tita AT, Szychowski JM, Boggess K, et al. Treatment for Mild Chronic Hypertension during Pregnancy. N Engl J Med. 2022;386(19):1781-1792. DOI: 10.1056/NEJMoa2201295 CHAP (Chronic Hypertension and Pregnancy) trial — randomised trial demonstrating that targeting BP <140/90 mmHg in chronic hypertension during pregnancy reduces adverse pregnancy outcomes without compromising fetal growth; labetalol and extended-release nifedipine were the predominant agents.
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018;71(19):e127-e248. DOI: 10.1016/j.jacc.2017.11.006 ACC/AHA hypertension guideline; defines BP thresholds and treatment goals. Beta-blockers (including labetalol) are not first-line for uncomplicated hypertension but appropriate when there is a compelling indication.
- American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy. Obstet Gynecol. 2019;133(1):e26-e50. DOI: 10.1097/AOG.0000000000003020 ACOG guidance establishing labetalol as one of the preferred first-line oral antihypertensives in chronic hypertension during pregnancy (alongside extended-release nifedipine; methyldopa and hydrochlorothiazide are secondary options).
- ACOG Committee Opinion No. 767: Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period. Obstet Gynecol. 2019;133(2):e174-e180. DOI: 10.1097/AOG.0000000000003075 ACOG protocol for emergent antihypertensive therapy in pregnancy; identifies IV labetalol, IV hydralazine, and immediate-release oral nifedipine as first-line agents for acute severe-range BP.
- Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke. Stroke. 2019;50(12):e344-e418. DOI: 10.1161/STR.0000000000000211 AHA/ASA acute ischaemic stroke guidelines; identifies IV labetalol as one of the preferred agents for blood-pressure lowering before and during thrombolytic therapy.
- van den Born BH, Lip GYH, Brguljan-Hitij J, et al. ESC Council on hypertension position document on the management of hypertensive emergencies. Eur Heart J Cardiovasc Pharmacother. 2019;5(1):37-46. DOI: 10.1093/ehjcvp/pvy032 European Society of Cardiology position paper defining the role of IV labetalol across hypertensive emergency scenarios including aortic dissection, intracerebral haemorrhage, and pre-eclampsia/eclampsia.
- Lenders JWM, Duh QY, Eisenhofer G, et al. Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2014;99(6):1915-1942. DOI: 10.1210/jc.2014-1498 Endocrine Society guidance on perioperative management of pheochromocytoma; emphasises adequate alpha-blockade before any beta-blocker initiation.
- MacCarthy EP, Bloomfield SS. Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. Pharmacotherapy. 1983;3(4):193-219. DOI: 10.1002/j.1875-9114.1983.tb03252.x Foundational review of labetalol pharmacology published shortly before its 1984 U.S. approval — describes the combined α/β-blockade profile, the four-stereoisomer composition, and the predominantly glucuronide metabolism.
- Goa KL, Benfield P, Sorkin EM. Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease. Drugs. 1989;37(5):583-627. DOI: 10.2165/00003495-198937050-00002 Comprehensive Drugs review covering labetalol’s stereochemistry, ADME, comparative efficacy versus other antihypertensives, and adverse-effect profile.